October 10, 2023
BURLINGTON, Ontario – October 5, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its placement financing (the “Financing”), the Company intends to issue common shares (“Common...
September 22, 2023
Corporate Update BURLINGTON, Ontario – September 22, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed on $310,000 in a second tranche of its previously announced private placement financing (the “Financing”) bringing the total...
September 14, 2023
BURLINGTON, Ontario – September 14 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated July 24, 2023 announcing a first tranche closing of approximately $1,500,000, the Company has received an extension from the...
August 4, 2023
BURLINGTON, Ontario – August 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce the voting results from its annual general and special meeting of shareholders (the “Meeting“) held on August 1, 2023. All matters presented to the...
July 26, 2023
Burlington, Ontario, July 24, 2023 – Mark Upsdell, a director and officer of Rapid Dose Therapeutics Corp. (the “Company”), announces that he has acquired ownership of additional securities of the Company by way of a non-brokered private placement pursuant to a settlement of debt. As...
July 24, 2023
BURLINGTON, Ontario – July 24, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed on $1,469,445 in a first tranche of its previously announced private placement financing (the “Financing”) for up to $5,000,000 of...
July 7, 2023
July 7, 2023 – Burlington, ON: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to share an update on its current progress in various segments of its business. The Annual General and Special Meeting of the shareholders of Rapid Dose Therapeutics...
June 29, 2023
Burlington, Ontario – June 28, 2023– Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), today reported its financial results for the year ended February 28, 2023. The Company is pleased to be able to report on its results for the fiscal year 2023...
June 5, 2023
BURLINGTON, Ontario – June 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete a private placement financing (the “Financing”) for up to $3,000,000 of gross proceeds, consisting of up to 3,000,000 units (the “Units”)...
May 18, 2023
BURLINGTON, Ontario – May 17, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that it has changed its auditor from MNP LLP (“Former Auditor”) to SRCO Professional Corporation, Chartered Professional Accountants (“Successor Auditor”). At the request of the Company, the...